ArticlePeerJ2026
Silver nanoparticles induce stress-associated upregulation of VEGF and FGF in fibroblasts as a compensatory response.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Silver nanoparticles (AgNPs) are widely incorporated into wound dressings and tissue-engineering scaffolds due to their antimicrobial properties; however, their direct effects on fibroblast biology and angiogenic signaling remain incompletely understood. Fibroblasts play a key role in tissue repair through secretion of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Elucidating how AgNPs influence fibroblast stress response and growth factor expression is critical for the safe design of regenerative biomaterials. Methods: Commercially standardized AgNPs were characterized by transmission electron microscopy (TEM) to determine particle size and dispersion. Mouse NIH/3T3 fibroblasts were exposed to various concentrations of AgNPs. Intracellular AgNP localization was visualized by TEM. Reactive oxygen species (ROS) generation was evaluated at 6 h using a dichloro-dihydro-fluorescein diacetate (DCFH-DA)-based assay, with additional cell-free controls to assess nanoparticle-probe interactions, including potential fluorescence quenching effects. Cell viability and migration were evaluated at 24 h using PrestoBlue and wound healing assays, respectively. VEGF and FGF protein expression were quantified by Western blot after 24 h of exposure. Results: AgNPs with an average diameter of 27.35 ± 11.92 nm were effectively internalized and accumulated in nuclei, perinuclear regions, mitochondria, and cytoplasmic vacuoles. At 6 h, ROS levels showed an increasing trend with AgNP exposure, although not statistically significant. Cell-free experiments demonstrated a dose-dependent reduction in DCF fluorescence in the presence of AgNPs, confirming nanoparticle-induced quenching and suggesting that intracellular ROS levels may be underestimated. At 24 h, AgNPs significantly reduced cell viability at 100 µg/mL, while migration exhibited a non-significant increase at 50 µg/mL. Despite these stress responses, VEGF and FGF levels increased significantly in a concentration-dependent manner, reaching statistical significance at the highest concentration. Conclusion: AgNP exposure induces intracellular accumulation and early oxidative stress, followed by upregulation of VEGF and FGF in fibroblasts. However, the absence of corresponding functional enhancement in cell migration, together with cytotoxic effects at higher concentrations, indicates that this response reflects a compensatory stress-associated mechanism rather than functional angiogenesis. These findings highlight the importance of validating nanoparticle-assay interactions and emphasize the need for careful dose optimization in the development of AgNP-based regenerative biomaterials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.